Novartis AG Common Stock (NVS)
133.10
+1.84 (1.40%)
NYSE · Last Trade: Nov 17th, 12:21 PM EST
Novartis (NVS) offers a strong 3.31% dividend yield with a history of reliable payouts and growth, backed by excellent profitability and financial health.
Via Chartmill · November 17, 2025
President Donald Trump announced a framework for a trade deal with Switzerland and Liechtenstein on Friday.
Via Benzinga · November 15, 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in mergers and acquisitions (M&A), the transformative power of artificial intelligence (AI), and an evolving investor landscape. With the global biotechnology
Via MarketMinute · November 14, 2025
Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presencestocktwits.com
Via Stocktwits · November 10, 2025
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This burgeoning field is set to dramatically enhance the shelf-life and effectiveness of medications, addressing long-standing inefficiencies in traditional drug development. By moving beyond time-consuming, empirical trial-and-error methods, [...]
Via TokenRing AI · November 14, 2025
San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This development marks a significant step forward in streamlining the notoriously complex and expensive process of bringing new therapies to patients, promising substantial reductions in costs and a [...]
Via TokenRing AI · November 13, 2025
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant parasite strains.
Via Benzinga · November 13, 2025
Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the heels of the company's announcement regarding the pricing of a $50 million underwritten public offering, a move that is
Via MarketMinute · November 12, 2025
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable tension between investor optimism and concerns over valuation. As of November 2025, the AI market stands at a pivotal juncture, with a concentrated surge in mega-cap AI players driving overall market [...]
Via TokenRing AI · November 10, 2025
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD) has successfully leveraged AI to design antibodies from scratch, achieving unprecedented atomic precision. This groundbreaking development, primarily driven by a sophisticated generative AI model [...]
Via TokenRing AI · November 5, 2025
The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%.
Via Investor's Business Daily · November 5, 2025
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]
Via TokenRing AI · November 4, 2025
Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.
Via Benzinga · November 3, 2025
iShares Core MSCI EAFE ETF (IEFA) Focuses on Developed Markets While Vanguard FTSE All-World ex-US ETF (VEU) Looks Globally
Via The Motley Fool · November 3, 2025
Trump offers help to cancer-stricken Dilbert creator Scott Adams after he appeals for assistance on social media. Adams seeks access to Pluvicto treatment for metastatic prostate cancer.
Via Benzinga · November 3, 2025
The Vanguard FTSE Developed Markets ETF (VEA) Offers Broader Diversification Than the SPDR Portfolio Developed World ex-US ETF (SPDW)
Via The Motley Fool · November 2, 2025
Vanguard VEA ETF Boasts Broader Portfolio Than State Street's SPDR SPDW
Via The Motley Fool · November 2, 2025
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly enhances the precision of drug development from initial discovery to commercial manufacturing. This fundamental shift is giving rise to the "TechBio" era, where AI is no longer merely a supporting tool but the [...]
Via TokenRing AI · November 1, 2025
The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by industry observers like PharmTech.com, rapid workforce upskilling is no longer a luxury but a critical necessity for companies aiming to thrive in this new era. The immediate significance [...]
Via TokenRing AI · October 31, 2025
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of excipient development. These "inactive" ingredients, which constitute the bulk of most drug formulations, are now at the forefront of an AI-driven innovation wave. By leveraging advanced [...]
Via TokenRing AI · October 31, 2025
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to market. Driven by advanced data integration and sophisticated analytics, AI is dramatically accelerating timelines, reducing costs, and significantly improving success rates across the entire drug development pipeline. This paradigm [...]
Via TokenRing AI · October 31, 2025
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late 2025, an established force, fundamentally reshaping drug development and operational workflows. This shift is not merely incremental but a comprehensive revolution, accelerating Research & [...]
Via TokenRing AI · October 31, 2025
Novartis is set to boost its developmental pipeline with this acquisition.
Via The Motley Fool · October 31, 2025
International dividend stocks are finally having their moment after years of underperformance, and this single Vanguard fund captures the opportunity with rock-bottom fees.
Via The Motley Fool · October 31, 2025